EN | DE

Dr. Chantal Bader

Über

Chantal Bader studierte Pharmazie an der Ruprecht-Karls-Universität Heidelberg, Deutschland (Approbation als Apothekerin, 2016). Nach ihrem Studium fertigte sie ihre Masterarbeit und 2016 die anschließende Promotion in der Abteilung von Rolf Müller am HIPS an, wo sie an der Isolierung und Charakterisierung verschiedener Naturstoffe aus Myxobakterien arbeitete. Unterstützt durch das DFG Walter-Benjamin-Stipendium wechselte sie an das Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology (Florida, USA), wo sie 2022 der Gruppe von Prof. Shen beitrat. Als Leiterin funktionsorientierter Screenings der dort ansässigen umfangreichen Extraktbibliothek erweiterte sie ihren Schwerpunkt auf die Entdeckung von Anti-Gram-negativen Antibiotika und Antiplasmodika aus Actinobakterien. Im Juli 2024 kehrte Chantal im Rahmen des Young AcademiXX-Programmes ans HIPS zurück.


2024

Discovery of the Pendulisporaceae: An extremotolerant myxobacterial family with distinct sporulation behavior and prolific specialized metabolism

Garcia R, Popoff A, Bader C, Löhr J, Walesch S, Walt C, Boldt J, Bunk B, Haeckl F, Gunesch A, …, Bach T, Müller R (2024)

Chem 10: 1-20DOI: 10.1016/j.chempr.2024.04.019

Elucidation of unusual biosynthesis and DnaN-targeting mode of action of potent anti-tuberculosis antibiotics Mycoplanecins

Fu C, Liu Y, Walt C, Rasheed S, Bader C, Lukat P, Neuber M, Haeckl F, Blankenfeldt W, Kalinina O, Müller R (2024)

Nat Commun 15 (1)DOI: 10.1038/s41467-024-44953-5

2023

Genome-Guided Discovery of the Myxobacterial Thiolactone-Containing Sorangibactins

Gao Y, Walt C, Bader C, Müller R (2023)

ACS chemical biology 18 (4): 924-932DOI: 10.1021/acschembio.3c00063

2022

Darobactins Exhibiting Superior Antibiotic Activity by Cryo-EM Structure Guided Biosynthetic Engineering

Seyfert C, Porten C, Yuan B, Deckarm S, Panter F, Bader C, Coetzee J, Deschner F, Tehrani K, Higgins P, …, Herrmann J, Müller R (2022)

Angewandte Chemie (International ed. in English)DOI: 10.1002/anie.202214094

Large-Scale Interlaboratory DI-FT-ICR MS Comparability Study Employing Various Systems

Forcisi S, Moritz F, Thompson C, Kanawati B, Uhl J, Afonso C, Bader C, Barsch A, Boughton B, Chu R, …, Laukien F, Schmitt-Kopplin P (2022)

Journal of the American Society for Mass SpectrometryDOI: 10.1021/jasms.2c00082

Identification and Biochemical Characterization of Pyrrolidinediones as Novel Inhibitors of the Bacterial Enzyme MurA

Fathalla R, Fröhner W, Bader C, Fischer P, Dahlem C, Chatterjee D, Mathea S, Kiemer A, Arthanari H, Müller R, …, Ducho C, Engel M (2022)

Journal of medicinal chemistryDOI: 10.1021/acs.jmedchem.2c01275

Thiamyxins: Structure and Biosynthesis of Myxobacterial RNA-Virus Inhibitors

Haack P, Harmrolfs K, Bader C, Garcia R, Gunesch A, Haid S, Popoff A, Voltz A, Kim H, Bartenschlager R, Pietschmann T, Müller R (2022)

Angewandte Chemie (International ed. in English)DOI: 10.1002/anie.202212946

Sandacrabins - Structurally Unique Antiviral RNA Polymerase Inhibitors from a Rare Myxobacterium

Bader C, Panter F, Garcia R, Tchesnokov E, Haid S, Walt C, Spröer C, Kiefer A, Götte M, Overmann J, Pietschmann T, Müller R (2022)

Chem. Eur. J. 28 (10)DOI: 10.1002/chem.202104484

2021

Improved broad-spectrum antibiotics against Gram-negative pathogens via darobactin biosynthetic pathway engineering

Groß S, Panter F, Pogorevc D, Seyfert C, Deckarm S, Bader C, Herrmann J, Müller R (2021)

Chem. Sci. 12 (35): 11882-11893DOI: 10.1039/d1sc02725e

Sesbanimide R, a Novel Cytotoxic Polyketide Produced by Magnetotactic Bacteria

Awal R, Haack P, Bader C, Riese C, Schüler D, Müller R (2021)

mBio 12 (3)DOI: 10.1128/mBio.00591-21

Search for the Active Ingredients from a 2-Aminothiazole DMSO Stock Solution with Antimalarial Activity

Ropponen H, Bader C, Diamanti E, Illarionov B, Rottmann M, Fischer M, Witschel M, Müller R, Hirsch A (2021)

ChemMedChem 16 (13): 2089-2093DOI: 10.1002/cmdc.202100067

Synergizing the potential of bacterial genomics and metabolomics to find novel antibiotics

Panter F, Bader C, Müller R (2021)

Chem. Sci. 12 (17): 5994-6010DOI: 10.1039/d0sc06919a

The Sandarazols are Cryptic and Structurally Unique Plasmid-Encoded Toxins from a Rare Myxobacterium*

Panter F, Bader C, Müller R (2021)

Angewandte Chemie (International ed. in English) 60 (15): 8081-8088DOI: 10.1002/anie.202014671

Expanding the Scope of Detectable Microbial Natural Products by Complementary Analytical Methods and Cultivation Systems

Bader C, Haack P, Panter F, Krug D, Müller R (2021)

Journal of natural products 84 (2): 268-277DOI: 10.1021/acs.jnatprod.0c00942

2020

Supercritical Fluid Extraction Enhances Discovery of Secondary Metabolites from Myxobacteria

Bader C, Neuber M, Panter F, Krug D, Müller R (2020)

Analytical chemistry 92 (23): 15403-15411DOI: 10.1021/acs.analchem.0c02995

In depth natural product discovery - Myxobacterial strains that provided multiple secondary metabolites

Bader C, Panter F, Müller R (2020)

Biotechnol Adv 39DOI: 10.1016/j.biotechadv.2019.107480

2019

Synthesis of New Cyclomarin Derivatives and Their Biological Evaluation towards Mycobacterium Tuberculosis and Plasmodium Falciparum

Kiefer A, Bader C, Held J, Esser A, Rybniker J, Empting M, Müller R, Kazmaier U (2019)

Chem. Eur. J. 25 (37): 8894-8902DOI: 10.1002/chem.201901640

Engineering Atypical Tetracycline Formation in Amycolatopsis sulphurea for the Production of Modified Chelocardin Antibiotics

Lukežic T, Fayad A, Bader C, Harmrolfs K, Bartuli J, Groß S, Lešnik U, Hennessen F, Herrmann J, Pikl Š, Petkovic H, Müller R (2019)

ACS Chem. Biol. 14 (3): 468-477DOI: 10.1021/acschembio.8b01125

2018

Concepts and Methods to Access Novel Antibiotics from Actinomycetes

Hug J, Bader C, Remškar M, Cirnski K, Müller R (2018)

Antibiotics 7 (2)DOI: 10.3390/antibiotics7020044